A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer
A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy
Sponsor: Laboratoires Leurquin Mediolanum
This PHASE2 trial investigates Prostate Cancer and is currently completed. Laboratoires Leurquin Mediolanum leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Oct 2018 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Laboratoires Leurquin Mediolanum
- Universita degli Studi di Genova
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Aviano, Italy , Barcelona, Spain , Bari, Italy , Brescia, Italy , Busto Arsizio, Italy , Candiolo, Italy , Genova, Italy , L'Hospitalet de Llobregat, Barcelona, Spain , Madrid, Spain and 8 more locations